Lenalidomide

Indian drug maker Dr Reddy’s shares fall after third-quarter profit misses forecasts

by
Indian drugmaker Dr Reddy's shares slide after Q3 profit miss

2025-01-24 11:48:00 : (Reuters) – Shares of Dr Reddy’s Laboratories fell 6% on Friday and were on track for their worst trading day in nearly nine months as sales and pricing pressure fell in key North American markets. Its third-quarter profit missed expectations. The generic drug maker was the top loser on the Nifty Pharma … Read more

Dr. Reddy’s to focus on complex products as growth driver to offset Revlimid revenue loss

by
The company’s Q3FY25 growth was largely driven by revenues from the NRT portfolio, as well as revenues from the India business and emerging markets.

2025-01-23 22:13:00 : Dr. Reddy’s is focused on a range of complex drugs, including GLP-1 (such as semaglutide), as well as biosimilars and consumer care, to offset the release of its blockbuster Revlimid (Revlimid) next year, an executive said. ) loss of exclusivity. Dr. Reddy CEO Erez Israel said the pharma giant has additional growth … Read more